Need to Minimize Bias When Surveying Patient Attitudes to Stopping cml Treatment
1
Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia
2
Hematology Directorate, SA Pathology School of Medicine, University of Adelaide
3
Flinders University, Adelaide, Australia
4
Medical Centre, Adelaide, Australia
5
Faculty of Medicine, Dentistry and Health Sciences, Sir Peter MacCallum Department of Oncology, Australia Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, The University of Melbourne, Locked Bag 1, A’Beckett Street, Victoria 8006, Australia
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2014, 21(6), 801-802; https://doi.org/10.3747/co.21.2177
Submission received: 3 September 2014
/
Revised: 4 October 2014
/
Accepted: 11 November 2014
/
Published: 1 December 2014
Excerpt
Note: In lieu of an abstract, this is an excerpt from the first page.
Sanford et al. reported results from an interviewassisted survey of chronic myeloid leukemia (CML) patients, which indicated that neither treatment compliance nor the occurrence of side effects significantly affected patient willingness to stop tyrosine kinase inhibitor treatment1.[...]
Share and Cite
MDPI and ACS Style
Villemagne–Sanchez, L.A.; Ross, D.M.; Schofield, P. Need to Minimize Bias When Surveying Patient Attitudes to Stopping cml Treatment. Curr. Oncol. 2014, 21, 801-802. https://doi.org/10.3747/co.21.2177
AMA Style
Villemagne–Sanchez LA, Ross DM, Schofield P. Need to Minimize Bias When Surveying Patient Attitudes to Stopping cml Treatment. Current Oncology. 2014; 21(6):801-802. https://doi.org/10.3747/co.21.2177
Chicago/Turabian StyleVillemagne–Sanchez, Lucia A., David M. Ross, and Penelope Schofield. 2014. "Need to Minimize Bias When Surveying Patient Attitudes to Stopping cml Treatment" Current Oncology 21, no. 6: 801-802. https://doi.org/10.3747/co.21.2177
